Presentation previews · Artwork labels are not verified filling specifications. Purchasing is not available.

AEVIA MED / VIALS
Tesamorelin
GHRH analogue studied in a specific HIV-associated fat-distribution condition.
FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR ANIMAL USE.
Do not inject, ingest or otherwise administer to humans or animals.
Research-use policy →Price
Price to confirm
Presentation status
Supplied visual concept. The printed amount is an artwork reference, not confirmation of AEVIA filling, formulation, physical state or use. It is not an application dose.
Research-only intended use
This product is intended solely for laboratory research conducted by appropriately trained personnel in suitable laboratory facilities. It must not be used in or on humans or animals, including by injection, ingestion or topical application.
It is not supplied for clinical, diagnostic, therapeutic, veterinary, cosmetic, food or supplement use. References to published studies describe research context only; they are not instructions or recommendations to use this product in people or animals.
The quantity stated on the container is the total supplied content, not an administration dose. Consult the applicable product documentation and safety data before laboratory handling. A product or batch record match does not establish suitability for human or animal use.
Research-use policy →Compound identity and research context · Separate from the exact product specification
What it is
Tesamorelin is a growth-hormone-releasing hormone analogue.
Biological target / research area
The growth-hormone axis and visceral adipose tissue in a defined clinical setting.
What the research examined
Evidence context: named product clinical context
The reference concerns the named US prescription product Egrifta WR, not an AEVIA product or a general weight-loss indication.
Evidence limitations
This is not a general weight-loss indication or proof of benefit for gym users. AEVIA product equivalence and local authorisation are not established.
Tesamorelin · 2 mg: this printed quantity identifies the artwork presentation. It is not a verified filling specification or an application dose.
Selected references
- Egrifta WR/tesamorelin — manufacturer product information ↗ · Reviewed 14/10/2026
Composition & specification
Verified product specifications and release documentation are pending. No dosing, preparation or administration instructions are provided.
Storage, safety & batch information
Product-specific storage, expiry and safety documentation must be confirmed for the exact released presentation. Use the exact-presentation batch reference lookup in the product guide. A record match does not authenticate physical contents.